NASDAQ:ATAI atai Life Sciences (ATAI) Stock Price, News & Analysis $2.19 -0.01 (-0.45%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$2.46 +0.27 (+12.10%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About atai Life Sciences Stock (NASDAQ:ATAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get atai Life Sciences alerts:Sign Up Key Stats Today's Range$2.16▼$2.2750-Day Range$1.38▼$2.4952-Week Range$1.03▼$3.02Volume1.34 million shsAverage Volume1.76 million shsMarket Capitalization$438.74 millionP/E RatioN/ADividend YieldN/APrice Target$8.67Consensus RatingBuy Company OverviewAtai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More… atai Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreATAI MarketRank™: atai Life Sciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 458th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus Ratingatai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coverageatai Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about atai Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of atai Life Sciences is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of atai Life Sciences is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratioatai Life Sciences has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about atai Life Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.00% of the float of atai Life Sciences has been sold short.Short Interest Ratio / Days to Coveratai Life Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in atai Life Sciences has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldatai Life Sciences does not currently pay a dividend.Dividend Growthatai Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.00% of the float of atai Life Sciences has been sold short.Short Interest Ratio / Days to Coveratai Life Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in atai Life Sciences has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.50 News Sentimentatai Life Sciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for atai Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, atai Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders26.80% of the stock of atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of atai Life Sciences is held by institutions.Read more about atai Life Sciences' insider trading history. Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATAI Stock News Headlinesatai Life Sciences Announces $50 Million Private Placement Financing2 hours ago | globenewswire.comatai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression2 hours ago | globenewswire.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.July 1 at 2:00 AM | Crypto 101 Media (Ad)ATAI - ATAI Life Sciences NV Price vs Fair Value - MorningstarJune 27, 2025 | morningstar.comMATAI - ATAI Life Sciences NV Valuation - MorningstarJune 27, 2025 | morningstar.comMMaxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price TargetJune 24, 2025 | msn.comatai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts sayJune 23, 2025 | proactiveinvestors.comPsychedelics regain momentum in 2025 on political tailwinds, clinical winsJune 19, 2025 | proactiveinvestors.comSee More Headlines ATAI Stock Analysis - Frequently Asked Questions How have ATAI shares performed this year? atai Life Sciences' stock was trading at $1.33 at the beginning of 2025. Since then, ATAI stock has increased by 64.7% and is now trading at $2.19. View the best growth stocks for 2025 here. How were atai Life Sciences' earnings last quarter? atai Life Sciences N.V. (NASDAQ:ATAI) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The firm earned $1.56 million during the quarter. When did atai Life Sciences IPO? atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. How do I buy shares of atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings5/14/2025Today7/01/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATAI CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+295.7%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.27 million Net MarginsN/A Pretax Margin-7,999.62% Return on Equity-102.10% Return on Assets-77.55% Debt Debt-to-Equity Ratio0.08 Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual Sales$310 thousand Price / Sales1,415.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book3.17Miscellaneous Outstanding Shares200,340,000Free Float146,647,000Market Cap$438.74 million OptionableOptionable Beta1.47 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:ATAI) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding atai Life Sciences N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.